Lexaria Bioscience Secures $2 Million in Direct Stock Offering to Fuel Corporate Growth

Lexaria Bioscience Corp. has announced a $2 million registered direct offering of common stock, signaling the company's strategic approach to capital raising and potential expansion of its innovative drug delivery platform.

The transaction involves the sale of 2 million shares at $1.00 per share, with H.C. Wainwright & Co. serving as the exclusive placement agent. The offering is expected to close on or around April 28, 2025, subject to standard closing conditions.

The capital raise represents a significant opportunity for Lexaria to bolster its financial resources. The company intends to allocate the net proceeds toward working capital and general corporate purposes, which could potentially support ongoing research and development efforts for its DehydraTECH drug delivery technology.

DehydraTECH, Lexaria's patented technology, has demonstrated potential in improving drug absorption and reducing side effects through oral delivery. With 48 patents already granted and additional patents pending worldwide, the company continues to position itself as an innovator in pharmaceutical formulation.

The offering is being conducted under an existing SEC-registered shelf registration statement, providing the company with flexibility in its capital-raising strategy. This approach allows Lexaria to access capital markets efficiently while maintaining compliance with regulatory requirements.

This financial move comes at a critical time for the company, potentially enabling further advancement of its research initiatives and technology development. The additional capital could support ongoing scientific research, patent development, and potential expansion of the company's technological capabilities.

Investors and industry observers will likely be watching closely to see how Lexaria utilizes these funds to drive innovation in drug delivery technologies and potentially create value for shareholders.